Medication info
Daehwa Lozartan Plus F Tablets

Daehwa Lozartan Plus F Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
10 tablets/blister x 3, 300 tablets/bottle
Approval status
Active

MFDS item code 201500534 · Approved 2015.01.30 · Insurance code 645604510

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start treatment with this medicine only when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Use of this medicine is not recommended in patients with more severe renal impairment, since loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this medicine is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium of 25 mg for these patients cannot be given with this medicine.
Child dose
Children (under 18 years): The losartan-hydrochlorothiazide combination should not be administered to children or adolescents because there is no experience with its use in this population.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for hypertensive patients whose blood pressure control is insufficient with monotherapy. It helps effectively lower blood pressure and reduces the risk of cardiovascular complications.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start treatment with this medicine only when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Use of this medicine is not recommended in patients with more severe renal impairment, since loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this medicine is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium of 25 mg for these patients cannot be given with this medicine.

Child dose

Children (under 18 years): The losartan-hydrochlorothiazide combination should not be administered to children or adolescents because there is no experience with its use in this population.

Precautions

This medication can cause serious harm, particularly to the fetus, if taken during pregnancy; therefore, it should not be used by women who are pregnant or may become pregnant. Patients who are allergic to this medication or have severely impaired kidney function, severely damaged liver function, or specific electrolyte imbalances should avoid using it. Patients with hypotension, kidney problems, liver disease, etc., require special caution when using this medication and should take it carefully as directed by a physician. This medication lowers blood pressure, and dizziness or drowsiness may occur during use, so caution is needed when driving or operating machinery. While taking this medication, renal function and electrolyte levels should be regularly monitored through blood tests, and care should be taken to prevent potassium levels from becoming too high or too low. This medication may interact with other antihypertensive medications, diuretics, and potassium supplements; therefore, if other medications are being taken, it is essential to inform the physician or pharmacist. The hydrochlorothiazide component may cause increased skin sensitivity to sunlight; thus, sun exposure should be avoided and skin protection should be ensured. If unusual symptoms or allergic reactions occur during use, medical consultation should be sought immediately, especially if swelling of the face, lips, or throat occurs, indicating a need for urgent treatment. It is not used in children or adolescents as safety and efficacy have not been established. Elderly patients may experience more frequent adverse reactions and require more caution when taking this medication. This medication should be taken strictly according to the prescribed dosage and administration and should not be stopped or altered without physician consent.

Side effects

  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
Show 124 more
  • skin peeling phenomenon
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • second degree atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramping
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neural hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disturbance
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechia
  • erythema
  • flushing
  • phototoxic reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision loss
  • taste abnormalities
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle cramps
  • agitation
  • renal failure
  • renal impairment
  • interstitial nephritis
  • skin mucosal syndrome
  • toxic epidermal necrolysis
  • temporary blurred vision
  • yellow vision
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythematous skin disease
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a tightly sealed container that prevents light exposure. It is important to maintain a storage temperature between 1 to 30 degrees Celsius to ensure the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

10 tablets/blister x 3, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.